Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

UK's Croda to sell industrial chemicals unit to Cargill in $1 billion deal

Published 22/12/2021, 08:06
© Reuters. FILE PHOTO: A Cargill logo is pictured on the Provimi Kliba and Protector animal nutrition factory in Lucens, Switzerland, September 22, 2016. REUTERS/Denis Balibouse/File Photo
CRDA
-
FTNMX552010
-

By Amna Karimi

(Reuters) - British speciality chemicals group Croda will sell most of its performance technologies and industrial chemicals division to commodities group Cargill Inc in a $1 billion deal, it said on Wednesday.

The sale of the unit, which makes low-carbon, sustainable additives and materials used in applications from food packaging to medical kits and devices, follows a strategic review as Croda shifts focus to its life sciences and consumer businesses.

"We will focus our capital and resources on delivering sustainable solutions and scaling our consumer, health and crop care technologies," CEO Steve Foots said in a statement.

In a separate statement, Cargill said the deal would help broaden its offerings to industrial manufacturers looking for sustainable options.

Croda is selling the majority of the business for an enterprise value of 915 million euros ($1 billion) on a cash-free, debt-free basis, it said.

The business raked in 470 million pounds ($626 million) in revenue last year.

Shares in the company, of the year's best performers in the FTSE 100 index, were down 1.5% at 1120 GMT.

Some investors expecting a higher price for the deal may have been disappointed, Hargreaves Lansdown (LON:HRGV) analyst Susannah Streeter said.

Croda has been focusing its performance tech division towards markets such as renewable technology and electric vehicles.

More recently, the Yorkshire-based company has been supplying vaccine delivery components to Pfizer (NYSE:PFE) for its COVID-19 vaccine, which helped it boost overall sales projections.

"Although revenues from Pfizer may wane, there is (an) expectation that there will be growing customer demand for a broader range of use of its products in medical treatments like oncology," Streeter said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"Recovery in consumer markets has also helped its personal care sector which focuses on ingredients for skin, hair, and cosmetic products."

($1 = 0.8873 euros)

($1 = 0.7509 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.